Full text
Earnings transcript
Read the complete earnings call transcript.
ABT
Abbott Laboratories
$102.87
0.49
(0.48%)
| Exchange: | NYSE |
| Market Cap: | 178.755B |
| Shares Outstanding: | 1.861B |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Robert Ford | |||||
| Full Time Employees: | 114000 | |||||
| Address: |
| |||||
| Website: | https://www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 40,109,000 | 41,950,000 | 44,328,000 |
| Gross Profit | 20,037,000 | 21,325,000 | 24,607,000 |
| EBITDA | 10,605,000 | 10,834,000 | 11,553,000 |
| Operating Income | 6,435,000 | 6,825,000 | 8,048,000 |
| Net Income | 5,723,000 | 13,402,000 | 6,524,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 73,214,000 | 81,414,000 | 0 |
| Total Liabilities | 34,387,000 | 33,513,000 | 641,000 |
| Total Stockholders Equity | 38,603,000 | 47,664,000 | 0 |
| Total Debt | 15,873,000 | 15,275,000 | 20,479,000 |
| Cash and Cash Equivalents | 6,896,000 | 7,616,000 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 7,261,000 | 8,558,000 | 9,566,000 |
| Capital Expenditure | -2,202,000 | -2,207,000 | 0 |
| Free Cash Flow | 5,059,000 | 6,351,000 | 9,566,000 |
| Net Income | 5,723,000 | 13,402,000 | 6,524,000 |
| Net Change in Cash | -2,986,000 | 720,000 | 906,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 64,187,948.413 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 64,925,024.243 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 64,669,333.333 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 17,175,337.786 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 17,372,563.693 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 17,304,146.212 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 14,509,725.978 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 14,726,825.668 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 14,651,512.498 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 17,261,009.840 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 17,459,219.527 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 17,390,460.774 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 8.390 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 8.430 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 8.310 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Performance: Abbott Laboratories reported a 3.8% increase in revenue for Q4 2025, as highlighted in the earnings call transcript. Key metrics such as net income and operating cash flow reflect consistent profitability, supported by a strong gross profit margin (TTM data). This indicates operational efficiency and resilience in core business segments.
- Innovation and Product Pipeline: The earnings call emphasized a robust pipeline of innovative products, contributing to sustained growth. Investments in R&D, evident from capital expenditure trends in cash flow statements, position ABT as a leader in its industry (Healthcare Equipment & Supplies) within the broader Healthcare sector.
- Strong Liquidity Position: Balance sheet data shows a healthy level of cash and cash equivalents alongside a favorable current ratio (TTM). This liquidity provides flexibility for strategic investments and debt management, reinforcing financial stability.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates ABT intrinsic value between $53.46 – $151.07 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about ABT valuation
Is Abbott Laboratories (ABT) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Abbott Laboratories (ABT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ABT a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ABT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ABT’s P/E ratio?
You can see ABT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ABT?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ABT a good long-term investment?
Whether ABT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ABT
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
0.48
Trading Metrics:
| Open: | 102.37 | Previous Close: | 102.38 | |
| Day Low: | 101.55 | Day High: | 103.47 | |
| Year Low: | 100.88 | Year High: | 139.06 | |
| Price Avg 50: | Price Avg 200: | |||
| Volume: | Average Volume: |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
Relevant news
